O157:H7 is the predominant cause of HUS [1, 2, 4, 6, 8] , but several non-O157:H7 serotypes have been emerging [2, 6, [8] [9] [10] [11] [12] .
Stxs are the major virulence factors implicated in the pathogenesis of HUS [4, 13] . These AB 5 toxins have been subdivided, on the basis of toxin neutralization assays and sequence analysis of stx genes, into 2 families, Stx1 and Stx2 [14] . Each family consists of the major Stx type and variants. The members of the Stx1 family are Stx1, Stx1c [15] , and Stx1d [16] . The more heterogeneous Stx2 family includes Stx2, Stx2c [17] , Stx2c2 [18] , Stx2d [19, 20] , Stx2e [21] , and Stx2f [22] . The Stx2d group comprises 2 independently described [19, 20] and distinct toxins, Stx2d EH250 [20] and Stx2d activatable [19] . The designation of the latter toxin has been derived from its capacity to be activated in its biological activity (demonstrated as a significant increase in its cytotoxicity for cultured cells) by mouse or human in testinal mucus [19] . This mucus activatibility differentiates Stx2d activatable from the other presently known Stxs [19, 23] .
The activator of Stx2d activatable in mouse mucus is an elastase that is highly homologous to human elastase IIIB [24] . The activation involves cleavage by the elastase of the last 2 Cterminal amino acids from an enzymatically active A subunit of Stx2d activatable [23] . As a result of this activation, STEC that produce Stx2d activatable are considerably more virulent in a streptomycin-treated mouse model of STEC infection (oral 50% lethal dose [LD 50 ] of !10 colony-forming units [cfu] ) than STEC producing Stx2 or Stx2c (LD 50 of 10 10 cfu) [19, 25] . The augmented virulence of Stx2d activatable -producing STEC in this model led to the hypothesis that the presence of an activatable Stx in STEC infecting humans and the activation of this Stx by human intestinal mucus during infection might result in increased virulence of such strains for humans [19] . However, the association of STEC that produce Stx2d activatable with human disease is poorly understood. Therefore, we investigated the prevalence of E. coli that produce Stx2d activatable in a large collection of STEC from clinically well-defined subjects, and we determined the association between production of Stx2d activatable by the infecting STEC and clinical outcome of the infection.
PATIENTS AND METHODS

Patients and strains.
A total of 922 STEC strains were isolated from 1994 to 2005 from stool samples obtained from individual, epidemiologically unrelated patients with HUS (339 strains), bloody diarrhea (51 strains), or nonbloody diarrhea (414 strains) or from asymptomatic carriers (118 strains), as described elsewhere [26, 27] . The strains belonged to 109 serotypes, as determined by a microtiter serotyping method [28] . Six hundred and eighty-three strains belonging to 30 serotypes contained the eae gene encoding the STEC adherence factor intimin [29] , and 239 strains belonging to 79 serotypes were eae negative (table 1) . Reference Stx2d activatable -producing E. coli strain B2F1 [19] , which was isolated from a patient with HUS [30] , was kindly provided by M. A. Karmali (Public Health Agency of Canada, Guelph, Canada).
Case definition. Patients with nonbloody diarrhea were defined as patients with у3 watery stools without visible blood per day. Patients with bloody diarrhea were defined as patients with у3 watery stools per day in which visible blood was noted in the stool. HUS was defined as a case of microangiopathic hemolytic anemia (hematocrit of !30% with peripheral evidence of intravascular hemolysis), thrombocytopenia (platelet count, !150,000 platelets/mm 3 ), and renal insufficiency (serum creatinine concentration greater than the upper limit of the normal range for age) [3] .
Detection of stx genes. The presence of the gene encoding Stx2d activatable in the 922 STEC strains was tested for using PCR with primers SLT-II-vc and CKS2 [18] and restriction analysis of the resulting 890-base pair (bp) amplicon with PstI [18] . PstI does not cleave the amplicon derived from stx 2d-activatable but cleaves this amplicon into 504-bp and 386-bp fragments if the target is stx 2 or stx 2c . The presence of stx 1 , stx 1c , stx 1d , stx 2 , stx 2c , stx 2dEH250 , and stx 2e was sought, as described elsewhere [15, 16, 21, 26] .
Isolation of mouse and human intestinal mucus. Mucus was isolated from the intestines (small and large) of 5 BALB mice and from pooled effluents obtained during colonoscopy from 3 humans [19] . The mucus preparations were adjusted to a protein concentration of 5 mg/mL with N-2-hydroxyethylpiperazine-N -2-ethanesulfonic acid (HEPES; 2.4 g/L) buffer (pH, 7.4) and were frozen in aliquots at Ϫ70ЊC.
Mucus and elastase activation assay. In the mucus activation assay [19] , sterile-filtered supernatants were preincubated (for 2 h at 37ЊC) with mouse or human intestinal mucus (1 mg/mL) or HEPES buffer and tested for cytotoxicity using Vero cells [31] . The level of activation was determined as the ratio between the cytotoxicity titer of the mucus-treated supernatant and that of the HEPES-treated supernatant. The toxin was considered to be activatable when the cytotoxicity titer increased at least 8-fold after incubation with the mouse intestinal mucus and at least 4-fold after incubation with the human colonic mucus. These cut-off values were based on the lowest levels of activation produced by mouse (8-fold) and human (4-fold) mucus in the supernatant of the control Stx2d activatable -producing strain B2F1. None of the mucus preparations were toxic to Vero cells at the concentration used.
In the elastase activation assay, supernatants were incubated (for 2 h at 37ЊC) with 1 unit of porcine pancreatic elastase (EC 3.4.21.36; Calbiochem) (used in lieu of mouse intestinal elastase, which is not commercially available) or with phospate elastase resuspension buffer (50 mM KH 2 PO 4 and 50 mM Na 2 HPO 4 ; pH, 7.6). The activation was determined as described above. The toxin was considered to be activatable when the cytotoxicity titer increased at least 4-fold after incubation with 1 unit of the elastase. This elastase concentration was chosen, because it is not toxic to Vero cells. In contrast, after 72 h, 5 and 10 units of the elastase caused cytotoxicities in titers of 1: 8 and 1:32, respectively.
Detection of other enteric bacterial pathogens in stools. Salmonella species, Shigella species, Yersinia enterocolitica, and Campylobacter jejuni were sought using standard procedures.
Serological investigation. IgM antibodies against lipopolysaccharide O157 in serum samples obtained from patients in the acute phase of HUS were detected using an immunoblot [32] .
Statistical analysis. [19, 23] . To investigate the mucus and elastase activatibility of all of these Stx types, 3-5 randomly selected strains that produced each of these Stxs as a sole Stx (31 strains altogether) were subjected to the activation assay. None displayed an increase in the cytotoxicity that fulfilled the definition of activation after incubation with either mouse or human intestinal mucus or elastase. Thus, all of these Stxs are very probably nonactivatable.
RESULTS
Prevalence of
Association between production of Stx2d activatable and clinical outcome of infection. Because all STEC strains that produced Stx2d activatable were eae negative, we analyzed the association between production of Stx2d activatable and clinical outcome of infection among individuals infected with eae-negative STEC. A stratified analysis including the 30 STEC strains that produced Stx2d activatable as the sole Stx was performed to avoid confounding by coproduction of nonactivatable Stx types (Stx1 and/or Stx2) by the other 29 strains and possible contribution of these Stxs to the clinical outcome.
The eae-negative STEC represent only small proportions of the total numbers of STEC isolated from patients with HUS (3.3%) and bloody diarrhea (12.0%) ( 
NOTE.
A, asymptomatic infection; BD, bloody diarrhea; D, diarrhea without visible blood; elastase, porcine pancreatic elastase (Calbiochem) (1 unit); HCM, human colonic mucus (1 mg/mL); HUS, hemolytic uremic syndrome; MIS, mouse intestinal mucus (1 mg/mL); NM, nonmotile; ONT, O antigen nontypeable; Orough, autoagglutinable strain.
a Cytotoxicity titer was defined as the highest dilution of the supernatant that caused cytotoxicity in 50% of Vero cells after 72 h of incubation. Data are given as geometric mean and range of titers from 3 repeated experiments (if only 1 titer value is given, the titers were identical in the 3 tests). b Defined as the ratio between the cytotoxicity titer after incubation with the respective mucus preparation or elastase and the cytotoxicity titer after incubation with a control buffer. Data are given as arithmetic means and single values from 3 repeated tests. c The patient died during acute phase of HUS. d No increase or a nonsignificant increase in the cytotoxicity titer after incubation with mucus or elastase. e Reference Stx2d activatable -producing strain [19] .
strain is a risk factor for a severe clinical outcome and for systemic progression of the infection to HUS. Characterization of patients infected with Stx2d activatable -producing STEC. The median age of 24 of 30 patients from whom the STEC strains that produced Stx2d activatable were isolated was 21 years (range, 1-89.5 years). Ages of 6 patients were unknown.
Ages were available for 5 of the 7 patients with HUS; 4 were adults (aged 21, 45, 57, and 64 years), and 1 was a 3-year-old child. One adult patient (a 64-year-old woman) died during the acute phase of HUS (tables 2 and 3). None of the 4 surviving patients with HUS for whom ages were known developed anti-O157 lipopolysaccharide IgM, demonstrating that E. coli O157: H7, which is the most common cause of STEC-associated HUS, was not missed by the microbiological evaluation. Serum samples from the remaining 3 patients with HUS were not available. Stool samples from all 30 patients infected with Stx2d activatable -producing STEC were negative for Salmonella species, Shigella species, Y. enterocolitica, and C. jejuni.
DISCUSSION
The clinical outcome of an infection due to STEC depends, in large part, on the Stx type produced by the infecting strain and on the presence of the eae gene, which encodes the adherence factor intimin. STEC that produce Stx2 or Stx2c, most of which possess eae [26] , cause severe disease, such as hemorrhagic colitis or HUS [10, 26, 33, 34] , whereas eae-negative STEC that produce Stx2d EH250 or Stx2e have been associated with uncomplicated diarrhea or asymptomatic infection [20, 21, 26] .
A subset of eae-negative STEC strains (i.e., STEC that produce Stx2d activatable ) differ from other eae-negative STEC strains by their strong association with severe disease. Our systematic analysis of the association between production of Stx2d activatable by the infecting STEC strain and the outcome of infection suggests that production of the activatable Stx may be a risk factor for the development of HUS after infection with eaenegative STEC, which otherwise only rarely causes HUS (table  4) [26, 33, 34] . By its association with severe outcome of the infection caused by eae-negative STEC, Stx2d activatable parallels the pathogenetic significance of Stx2 among eae-positive STEC [26, 33, 34] . However, in contrast to Stx2, which is associated with HUS development in children !5 years old [26] , most of the patients with HUS from whom we isolated Stx2d activatableproducing STEC were adults.
From a practical standpoint, our data demonstrate a need for a rapid and comprehensive subtyping of stx genes in STEC isolates by microbiologists and the immediate interpretation and reporting of results to clinicians. The information about the presence of the gene encoding Stx2d activatable in the infecting STEC could alert the treating physician that a patient is at risk for developing HUS, even though this strain lacks eae. Such a patient, if symptomatic, should be monitored for HUS development and given intravenous volume expansion [35] , which has been associated with a reduced risk of anuric renal failure in patients with HUS due to STEC O157:H7. Although the precise risk of developing HUS for a patient with diarrhea who is infected with an Stx2d activatable -producing STEC is unknown, these organisms might have consequences for infected humans similar to those associated with STEC O157; we believe that it would be appropriate to treat such patients similarly, at least until more data emerge. Because the activatable Stx was expressed by the majority of STEC isolates that contained stx 2d-activatable as the sole stx (30 of 31 isolates), we propose that the identification of the gene itself, without a need to perform a labor-intensive mucus or elastase activation assay, might be a sufficient predictor for the highly pathogenic potential of the isolated STEC. These data also demonstrate the need for more extensive, rapid, and accurate characterization of infecting strains, beyond the mere assessment of their ability to produce Stx. The increased pathogenicity of STEC harboring stx 2d-activatable for humans, as demonstrated in our study, has been suspected on the basis of previous occasional isolations of such strains from severely ill persons, including patients with bloody diarrhea or HUS [30, 34, 36] . In a study from the United States [18] , STEC that produced Stx2d activatable were associated with a more severe course of diarrhea, as demonstrated by a higher rate of diagnostic or therapeutic procedures in patients infected by such strains; however, the association with bloody diarrhea did not reach statistical significance. The apparent disproportionate virulence of Stx2d activatable -producing STEC for humans is also suggested by their ability to cause outbreaks, which are exceptionally associated with eae-negative STEC [37] . Of note, the eae-negative STEC strain O104:H21, which caused a large milkborne outbreak of hemorrhagic colitis in the United States [38] , produces Stx2d activatable [23] .
Reasons for the excess virulence of strains producing Stx2d activatable are presently not understood, but they are probably complex. It has been suggested [19] that the production of an activatable toxin might compensate for the lack of intimin, which mediates the intimate intestinal adhesion of eae-positive STEC [29] and, thus, enables an efficient delivery of Stx from the intestine to the bloodstream. Another plausible explanation might be a high rate of the expression of Stx2d activatable in strains that contain this gene, as observed in our study. In contrast, a subset of eae-negative STEC that harbor structurally intact genes encoding other Stx2 variants (e.g., Stx2d EH250 and Stx2e) [39] do not secrete Stxs [34, 39] . Alternatively, STEC that produce Stx2d activatable might express additional, yet unidentified, virulence factors that could contribute to their high human virulence. It should be noted that production of the activatable Stx is not essential for the ability of eae-negative STEC to cause HUS. Four eae-negative HUS isolates in this study (table 4) and an eae-negative STEC O113:H21 that caused an HUS cluster in Australia [37] possessed nonactivatable Stxs. Recently, a plant-based oral vaccine for protection against systemic intoxication caused by Stx2 has been developed [40] . The ability of this vaccine to completely protect mice from the renal pathology and resulting death caused by Stx2d activatable -producing strain B2F1 [40] is promising and might be useful in preventing human diseases caused by such strains.
In summary, we identified Stx2d activatable as an important cause of severe human disease caused by STEC. Diagnostic strategies should be modified to identify allelic variants in STEC, and symptomatic patients should be considered to be at increased risk of microangiopathic sequelae and treated accordingly.
